Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122157) titled 'Clinical Study on the Efficacy and Safety of Luspatercept in Combination with Thalidomide for Adult Patients with ß-Thalassaemia' on April 9.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The 923rd Hospital of the Joint Logistics Support Force of the People's Liberation Army
Condition:
ß-Thalassaemia
Intervention:
Luspatercept + Thalidomide Group:Luspatercept: 1.0 mg/kg, subcutaneous (SC) administration, every 21 days
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2026-02-01
Target Sample Size: Luspatercept + Thalidomide Group:30;
Count...